Relmada Therapeutics Inc

NASDAQ:RLMD   3:59:55 PM EDT
35.41
-1.61 (-4.35%)
Regulatory, Other Pre-Announcement

Relmada Therapeutics Expects To Report Top-Line Data From Reliance III Trial Early Next Quarter

Published: 09/20/2022 13:37 GMT
Relmada Therapeutics Inc (RLMD) - Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 Reliance Iii Trial for Rel-1017 As a Monotherapy for Major Depressive Disorder.
Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 Reliance Iii Trial for Rel-1017 As a Monotherapy for Major Depressive Disorder.
Relmada Therapeutics Inc - Expects to Report Top-line Data From Reliance Iii Trial Early Next Quarter.